DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20213747

Assessment of safety and efficacy of a dietary supplement KaraLiv™ in supporting liver health: a double-blind, parallel, placebo-controlled randomized clinical trial

Krishna Rajendran, Rajendran Ramaswamy, Kudiganti Venkateshwarlu, Ravikumar Rajendran, K. Sunil Naik

Abstract


Background: The liver is responsible for many critical functions within the body. If the liver becomes diseased or injured, loss of those critical functions can cause significant damage to the body. KaraLivTM is a novel herbal formulation which contains a blend of different herbal extract ingredients. The current study tested the safety and efficacy of KaraLivTM versus a placebo control in supporting liver function.

Methods: The study is a randomized, double-blind, parallel, and placebo-controlled study. A total of 60 patients were divided into 2 groups of 30 each. One group was given KaraLivTM and the other group was given a placebo for a period of 56 days. Treatment results were assessed by evaluating the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, and alkaline phosphatase (ALP) in both groups.

Results: The herbal supplement KaraLivTM significantly supported healthy liver function compared to the placebo following the 56 days of treatment. The treatment (KaraLivTM) group showed a statistically significant improvement in assessed liver enzyme levels compared to the placebo group.

Conclusions: The all-natural herbal supplement KaraLivTM is a safe and effective product that can significantly help support healthy liver function.


Keywords


Liver, Herbal supplement, Clinical trial, Liver enzymes

Full Text:

PDF

References


Ward FM, Daly MJ. Hepatic disease. Walker R, Edwards C, editors. Clinical Pharmacy and Therapeutics. New York: Churchill Livingstone. 1999;195-212.

Dash S, Pattanaik S, Rout SS, Bose A. Evaluation of hepatoprotective activity of the aerial parts of phyllanthus reticulates against paracetamol induced hepatic damage in rats. Asian J Pharm Clin Res. 2015;8(4):221-4.

Cornelius CE. Liver function. Clinical biochemistry of domestic animals. Academic Press. 1980;201-57.

Maher JJ. Exploring alcohol’s effects on liver function. Alcohol Health Res World 1997;21(1):5.

Karan M, Vasisht K, Handa SS. Antihepatotoxic activity of Swertia chirata on carbon tetrachloride induced hepatotoxicity in rats. Phytother Res. 1999;13(1):24-30.

Chaterrjee TK. Medicinal Plants with Hepatoprotective Properties, Herbal Options. Calcutta: Books and Applied Allied (P) Ltd. 2000;143.

Thyagarajan SP, Jayaram S, Gopalakrishnan V, Hari R, Jeyakumar P, Sripathi MS. Herbal medicines for liver diseases in India. J Gastroenterol Hepatol. 2002;17:370-6.

Mardani S, Khodadadi S, Ahmadi A, Kazemi E, Rafieian-kopaei M. The effects of Momordica charantia on liver function and histological structure. Ann Res Antioxid. 2016;1(1):12.

Al Zarzour RH, Ahmad M, Asmawi MZ, Kaur G, Saeed M, Al-Mansoub, et al. Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats. Nutrients. 2017;9(7):766.

Chua LS. Review on liver inflammation and antiinflammatory activity of Andrographis paniculata for hepatoprotection. Phytother Res. 2014;28(11):1589-98.

Fu R, Zhang Y, Guo Y, Peng T, Chen F. Hepatoprotection using Brassica rapa var. rapa L. seeds and its bioactive compound, sinapine thiocyanate, for CCl4-induced liver injury. J Funct Foods. 2016;22:73-81.

Acharya SR, Acharya NS, Bhangale JO, Shah SK, Pandya SS. Antioxidant and hepatoprotective action of Asparagus racemosus wild root extracts. Indian J Exp Biol. 2012;50(11):795-801.

Rafie R, Hosseini SA, Hajiani E, Malehi AS, Mard SA. Effect of Ginger Powder Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Clin Exp Gastroenterol. 2020;13:35-45.

Lala V, Goyal A, Bansal P, Minter DA. Liver function tests. StatPearls. 2020.

Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss-Isakov N, Hahn M, Webb M, Shibolet O, et al. Serum malondialdehyde is associated with non-alcoholic fatty liver and related liver damage differentially in men and women. Antioxidants. 2020;9(7):578.

Younus H. Therapeutic potentials of superoxide dismutase. Int J Health Sci (Qassim). 2018;12(3):88-93.

Whitfield JB. Gamma Glutamyl Transferase. Criti Rev Clin Lab Sci. 2001;38(4):263-355.

Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47(4):1363-70.

Panteghini M. Aspartate aminotransferase isoenzymes. Clinical biochemistry. 1990;23(4):311-9.

Sharma U, Pal D, Prasad R. Alkaline phosphatase: an overview. Indian J Clin Biochem. 2014;29(3):269-78.

Hamoud AR, Weaver L, Stec DE, Hinds TD. Bilirubin in the liver–gut signaling axis. Trends Endocrinol Metabol. 2018;29(3):140-50.

Vuppalanchi R, Juluri R, Bell LN, Ghabril M, Kamendulis L, Klaunig JE, et al. Oxidative stress in chronic liver disease: relationship between peripheral and hepatic measurements. Am J Med Sci. 2011;342(4):314-7.

Di Naso FC, Simões Dias A, Porawski M, Marroni NA. Exogenous superoxidedismutase: action on liver oxidative stress in animals with streptozotocin-induced diabetes. Exp Diabetes Res. 2011;754132.

Courtay C, Oster T, Michelet F, Visvikis A, Diederich M, Wellman M et al. γ-Glutamyltransferase: Nucleotide sequence of the human pancreatic cDNA. Biochem Pharmacol. 1992;43(12):2527-33.